



Correction: Clinical and Economic Benefit of Advanced Therapies for the Treatment of Active Ankylosing Spondylitis

Jessica A. Walsh · Christopher D. Saffore · Eric B. Collins · Andrew Ostor

Published online: November 29, 2023
© The Author(s) 2023

Correction: **Rheumatol Ther (2023) 10:1385–1398**
<https://doi.org/10.1007/s40744-023-00586-6>

In this article the treatment cost was incorrectly calculated from 12-week cost but should have been calculated from 16-week costs. The corrected sentences are given below.

The penultimate sentence under the heading Methods in Abstract section should have read “Cost per ASAS40 responder (CPR) was

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40744-023-00626-1>.

The original article can be found online at <https://doi.org/10.1007/s40744-023-00586-6>.

J. A. Walsh (✉)
Division of Rheumatology, Clinic 2, Salt Lake City Veterans Affairs and University of Utah, 50 North Medical Drive, Salt Lake City, UT 84132, USA
e-mail: Jessica.Walsh@hsc.utah.edu

C. D. Saffore
AbbVie Inc., North Chicago, IL, USA

E. B. Collins
Medicus Economics LLC, Boston, MA, USA

A. Ostor
Cabrine Medical Center, Monash University, Melbourne, Australia

A. Ostor
Australian National University, Canberra, Australia

calculated as the 16-week treatment costs divided by ASAS40 response rates.”

The last sentence under the heading Costs in Methods section should have read “The dosing schedules and unit and administration costs were used to calculate the costs for 16-week treatment for each therapy.”

The second sentence in third paragraph under the heading Statistical Methods in Methods section should have read “CPR was calculated as the 16-week treatment costs for each advanced therapy divided by NMA-estimated ASAS40 absolute response rates.”

The header “Cost Per Responder Over 12 Weeks” under Results section should have read “Cost Per Responder Over 16 Weeks.”

Figure 4 caption should have read “Cost per responder for ASAS40 over 16 weeks in bio-naïve (a) and bio-IR (b) patients with AS...”

In the Supplementary PDF for this article, the Supplementary Fig. 4 title should have read “Supplementary Fig. 4: Cost per responder for ASAS40 over 16 weeks among TNF-IR patients.”

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative

Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative

Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.